Autoregulated Bispecific Antibodies: Harnessing Built-In Feedback to Improve Safety & Durability
- AutoRegulation (AR) is a modular antibody technology that embeds a negative feedback loop to provide precision control over activity, enhancing activity, reducing toxicity and widening the therapeutic index
- Demonstration of applying AR across indications and modalities using a factor VIII mimetic in haemophilia to mitigate thrombosis risk. AR has also been applied to T-cell engagers for oncology and autoimmunity to control CRS, ICANS and cytopenias and prevent T-cell exhaustion, whilst maintaining efficacy
- Advancing NVG-222, the most mature AutoRegulated T-cell engager into clinic with imminent first-patient dosing, presenting IND-enabling studies that helped inform clinical strategy